Aktienanalyse zu Qiagen NV (QGEN)QGENQiagen NV

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight. It operates in the Healthcare sector.

Qiagen NV is a good buy right now due to its current price of $46.13, which is below the analyst price targets of $50 and $55, indicating potential upside. The forward P/E ratio of 13.53 suggests the stock is undervalued compared to its earnings potential. Additionally, the RSI of 67.15 indicates strong momentum, although it is approaching overbought territory. The main risk is the hedge fund selling trend, which has increased by 286.76% over the last quarter, indicating potential negative sentiment among institutional investors.

10 analysts cover QGEN: 3 rate it Buy, 7 Hold and 0 Sell. The average price target is 50.57.